Review



dy268  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems dy268
    Dy268, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/DY+268/pmc08891600-103-18-24
    Average 94 stars, based on 10 article reviews
    dy268 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Over Expression:

    Article Title: DMRT2 Interacts With FXR and Improves Insulin Resistance in Adipocytes and a Mouse Model
    Article Snippet: The mouse GLUT4 promoter was cloned by PCR and cloned into psiCheck-2 vector (Promega, Madison, WI, USA) using homologous recombination methods. .. The reporter vector or DMRT2 overexpression vector was co-transfected in 3T3-L1 adipocytes in the presence or absence of DY268 (5 μM for 24 h, R&D Systems). .. Forty-eight hours after transfection, luciferase alterations were determined in a Dual-luciferase Reporter Assay System (Promega, USA).



    Similar Products

    fxr antagonist dy268  (MedChemExpress)
    94
    MedChemExpress fxr antagonist dy268
    Fxr Antagonist Dy268, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/DY268/pm41819510-68-0-8
    Average 94 stars, based on 1 article reviews
    fxr antagonist dy268 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    antagonist dy268  (TargetMol)
    93
    TargetMol antagonist dy268
    Antagonist Dy268, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/DY268/pmc12871761-49-14-34
    Average 93 stars, based on 1 article reviews
    antagonist dy268 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    dy268  (Tocris)
    94
    Tocris dy268
    Capan-2 cells were treated with DMSO or LCA (0.03 µM) and/or 5 µM CINPA1, <t>DY268,</t> NF449, GSK2033, and ketoconazole for 48 h. ( A ) Cell invasion was measured using Corning Matrigel invasion chambers. B β-catenin and NRF2 protein levels were measured by western blotting (representative figure). TGR5, FXR, and VDR bile acid receptors were transiently silenced in Capan-2 cells using the corresponding siRNA. A control group was transfected with negative control siRNA. After 48 h, C the transfection efficiency was assessed by qPCR, and D β-catenin expression was assessed by western blotting ( n = 3). Data are presented as means ± SEM. Transfection efficiencies were compared with one-way ANOVA and Dunnett’s post hoc. Control siRNA vs. LCA/siRNA treated groups were compared with paired t -tests. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001. DMSO dimethyl sulfoxide, FXR farnesoid X-activated receptor, LCA lithocholic acid, NRF2 nuclear factor, erythroid 2-like 2, TGR5 Takeda G-protein coupled receptor,VDR vitamin D receptor.
    Dy268, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/DY+268/pmc11116504-239-9-19
    Average 94 stars, based on 1 article reviews
    dy268 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    dy268 (fxr antagonist)  (Axon Medchem LLC)
    90
    Axon Medchem LLC dy268 (fxr antagonist)
    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
    Dy268 (Fxr Antagonist), supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/dy+268+2561/pmc09214809-132-0-5
    Average 90 stars, based on 1 article reviews
    dy268 (fxr antagonist) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    dy268  (R&D Systems)
    94
    R&D Systems dy268
    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
    Dy268, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/DY+268/pmc08891600-103-18-24
    Average 94 stars, based on 1 article reviews
    dy268 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    3t3 l1 adipocytes  (R&D Systems)
    90
    R&D Systems 3t3 l1 adipocytes
    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
    3t3 L1 Adipocytes, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dy268/Human+NT-4+DuoSet+ELISA/pmc08891600-103-10-24
    Average 90 stars, based on 1 article reviews
    3t3 l1 adipocytes - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Capan-2 cells were treated with DMSO or LCA (0.03 µM) and/or 5 µM CINPA1, DY268, NF449, GSK2033, and ketoconazole for 48 h. ( A ) Cell invasion was measured using Corning Matrigel invasion chambers. B β-catenin and NRF2 protein levels were measured by western blotting (representative figure). TGR5, FXR, and VDR bile acid receptors were transiently silenced in Capan-2 cells using the corresponding siRNA. A control group was transfected with negative control siRNA. After 48 h, C the transfection efficiency was assessed by qPCR, and D β-catenin expression was assessed by western blotting ( n = 3). Data are presented as means ± SEM. Transfection efficiencies were compared with one-way ANOVA and Dunnett’s post hoc. Control siRNA vs. LCA/siRNA treated groups were compared with paired t -tests. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001. DMSO dimethyl sulfoxide, FXR farnesoid X-activated receptor, LCA lithocholic acid, NRF2 nuclear factor, erythroid 2-like 2, TGR5 Takeda G-protein coupled receptor,VDR vitamin D receptor.

    Journal: Cell Death Discovery

    Article Title: The bacterial metabolite, lithocholic acid, has antineoplastic effects in pancreatic adenocarcinoma

    doi: 10.1038/s41420-024-02023-1

    Figure Lengend Snippet: Capan-2 cells were treated with DMSO or LCA (0.03 µM) and/or 5 µM CINPA1, DY268, NF449, GSK2033, and ketoconazole for 48 h. ( A ) Cell invasion was measured using Corning Matrigel invasion chambers. B β-catenin and NRF2 protein levels were measured by western blotting (representative figure). TGR5, FXR, and VDR bile acid receptors were transiently silenced in Capan-2 cells using the corresponding siRNA. A control group was transfected with negative control siRNA. After 48 h, C the transfection efficiency was assessed by qPCR, and D β-catenin expression was assessed by western blotting ( n = 3). Data are presented as means ± SEM. Transfection efficiencies were compared with one-way ANOVA and Dunnett’s post hoc. Control siRNA vs. LCA/siRNA treated groups were compared with paired t -tests. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001. DMSO dimethyl sulfoxide, FXR farnesoid X-activated receptor, LCA lithocholic acid, NRF2 nuclear factor, erythroid 2-like 2, TGR5 Takeda G-protein coupled receptor,VDR vitamin D receptor.

    Article Snippet: BA receptor antagonists (NF449 [ ], CINPA1 [ ], DY268 [ ], and GSK2033 [ ]) were acquired from Tocris Bioscience (Bristol, UK), and ketoconazole [ ] was purchased from Sigma-Aldrich.

    Techniques: Western Blot, Control, Transfection, Negative Control, Expressing

    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

    Journal: The Journal of Biological Chemistry

    Article Title: Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway

    doi: 10.1016/j.jbc.2022.102056

    Figure Lengend Snippet: Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

    Article Snippet: DY268 (FXR antagonist) was from Axon Medchem.

    Techniques: Gene Expression, Control